JavaScript is off. Please enable to view full site.

FDA lifts partial clinical hold on Gilead's blood cancer drug trials

FDA lifts partial clinical hold on Gilead's blood cancer drug trials

Tuesday, April 12, 2022, 17:15 GMT+7
FDA lifts partial clinical hold on Gilead's blood cancer drug trials
A Gilead Sciences, Inc. logo is seen outside the company headquarters in Foster City, California, U.S. May 1, 2018. Photo: Reuters

Gilead Sciences Inc said on Monday the U.S. Food and Drug Administration had lifted the partial clinical hold placed on its trials testing a blood cancer drug combination.

The FDA removed the hold after a review of the safety data from each trial, the company said.

The health regulator had placed the hold on five cancer trials in January due to an imbalance in suspected and unexpected serious side effects between different arms of the studies that were reported by investigators of the trials.

The trials were evaluating the combination of magrolimab and another drug azacitidine for treatment of two types of blood cancers called myelodysplastic syndrome and acute myeloid leukemia.

Magrolimab became part of Gilead's pipeline through the acquisition of Forty Seven Inc for $4.9 billion in 2020.

Reuters

More

Read more

;

Photos

VIDEOS

‘Taste of Australia’ gala dinner held in Ho Chi Minh City after 2-year hiatus

Taste of Australia Gala Reception has returned to the Park Hyatt Hotel in Ho Chi Minh City's District 1 after a two-year hiatus due to the COVID-19 pandemic

Vietnamese woman gives unconditional love to hundreds of adopted children

Despite her own immense hardship, she has taken in and cared for hundreds of orphans over the past three decades.

Vietnam’s Mekong Delta celebrates spring with ‘hat boi’ performances

The art form is so popular that it attracts people from all ages in the Mekong Delta

Latest news